People · Operator
Named in public records as an officer, director or promoter · active 2017–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Celularity Inc. | — | Biotechnology | Series C | $117.7M | $3.2B | 2017 |
| Celularity Inc | — | Biotechnology | Series B | $41.8M | $8.1M | 2022 |
Peter R. Diamandis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter R. Diamandis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John R. Haines | 2 | 2 |
| PETER DIAMANDIS | 1 | 10 |
| John Sculley | 1 | 6 |
| Robert J Hariri | 1 | 5 |
| Robert Hariri | 1 | 5 |
| Timothy Smith | 1 | 5 |
| Henry Ji | 1 | 5 |
| Andrew Pecora | 1 | 4 |
| Tim Smith | 1 | 4 |
| Robin L. Smith | 1 | 4 |
| CARLOS RAMIREZ | 1 | 4 |
| Dean C. Kehler | 1 | 4 |
| STEPHEN A BRIGIDO | 1 | 3 |
| Andrew Von Eschenbach | 1 | 3 |
| Andrew L. Pecora | 1 | 3 |
| Jaisim Shah | 1 | 3 |
| LIM KOK THAY | 1 | 2 |
| Jay R. Bloom | 1 | 2 |
| Andrew C. Von Eschenbach | 1 | 2 |
| Kok Thay Lim | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.